96 / 144
376
levodopa-induced dyskinesias. Annals of neurology.
1999;46(5):732-8.
19. Vitek JL, Giroux M. Physiology of hypokinetic and hyperkinetic
movement disorders: model for dyskinesia. Ann Neurol.
2000;47(4 Suppl 1):S131-40.
20. de Lau LM, Breteler MM. Epidemiology of Parkinson’s disease.
The Lancet Neurology. 2006;5(6):525-35.
21. Haaxma CA, Bloem BR, Borm GF, Oyen WJ, Leenders KL, Eshuis
S, et al. Gender differences in Parkinson’s disease. Journal of
neurology, neurosurgery, and psychiatry. 2007;78(8):819-
24.
22. Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD,
Leimpeter A, Bloch DA, et al. Incidence of Parkinson’s disease:
variation by age, gender, and race/ethnicity. American
journal of epidemiology. 2003;157(11):1015-22.
23. Schrag A, Ben-Shlomo Y, Brown R, Marsden CD, Quinn N.
Young-onset Parkinson’s disease revisited--clinical features,
natural history, and mortality. Movement disorders : official
journal of the Movement Disorder Society. 1998;13(6):885-
94.
24. Kalia LV, Lang AE. Parkinson’s disease. Lancet. 2015.
25. Noyce AJ, Bestwick JP, Silveira-Moriyama L, Hawkes CH,
Giovannoni G, Lees AJ, et al. Meta-analysis of early nonmotor
features and risk factors for Parkinson disease. Annals of
neurology. 2012;72(6):893-901.
26. Suchowersky O, Reich S, Perlmutter J, Zesiewicz T, Gronseth
G, Weiner WJ. Practice Parameter: diagnosis and prognosis
of new onset Parkinson disease (an evidence-based
review): report of the Quality Standards Subcommittee
of the American Academy of Neurology. Neurology.
2006;66(7):968-75.
27. Driver JA, Kurth T, Buring JE, Gaziano JM, Logroscino G.
Parkinson disease and risk of mortality: a prospective
comorbidity-matched cohort study. Neurology. 2008;70(16
Pt 2):1423-30.
28. Lang AE, Lozano AM. Parkinson’s disease. First of two parts.
The New England journal of medicine. 1998;339(15):1044-
53.
29. Rodriguez-Oroz MC, Jahanshahi M, Krack P, Litvan I,
Macias R, Bezard E, et al. Initial clinical manifestations
of Parkinson’s disease: features and pathophysiological
mechanisms. Lancet Neurol. 2009;8(12):1128-39.
30. Fahn S, Libsch LR, Cutler RW. Monoamines in the human
neostriatum: topographic distribution in normals and
in Parkinson’s disease and their role in akinesia, rigidity,
chorea, and tremor. Journal of the neurological sciences.
1971;14(4):427-55.
31. Marras C, Lang A. Parkinson’s disease subtypes: lost in
translation? Journal of neurology, neurosurgery, and
psychiatry. 2013;84(4):409-15.
32. Jankovic J, McDermott M, Carter J, Gauthier S, Goetz C,
Golbe L, et al. Variable expression of Parkinson’s disease:
a base-line analysis of the DATATOP cohort. The Parkinson
Study Group. Neurology. 1990;40(10):1529-34.
33. Muslimovic D, Post B, Speelman JD, De Haan RJ, Schmand
B. Cognitive decline in Parkinson’s disease: a prospective
longitudinal
study.
Journal
of
the
International
Neuropsychological Society : JINS. 2009;15(3):426-37.
34. Chaudhuri KR, Odin P, Antonini A, Martinez-Martin P.
Parkinson’s disease: the non-motor issues. Parkinsonism
Relat Disord. 2011;17(10):717-23.
35. Duncan GW, Khoo TK, Yarnall AJ, O’Brien JT, Coleman SY,
Brooks DJ, et al. Health-related quality of life in early
Parkinson’s disease: the impact of nonmotor symptoms.
Movement disorders : official journal of the Movement
Disorder Society. 2014;29(2):195-202.
36. Tolosa E, Compta Y, Gaig C. The premotor phase of Parkinson’s
disease. Parkinsonism & related disorders. 2007;13
Suppl:S2-7.
37. Siderowf A, Lang AE. Premotor Parkinson’s disease: concepts
and definitions. Movement disorders : official journal of the
Movement Disorder Society. 2012;27(5):608-16.
38. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN,
Braak E. Staging of brain pathology related to sporadic
Parkinson’s disease. Neurobiol Aging. 2003;24(2):197-211.
39. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG.
The Sydney multicenter study of Parkinson’s disease:
the inevitability of dementia at 20 years. Movement
disorders: official journal of the Movement Disorder Society.
2008;23(6):837-44.
40. Emre M. Clinical features, pathophysiology and treatment of
dementia associated with Parkinson’s disease. Handbook of
clinical neurology. 2007;83:401-19.
41. Aarsland D, Larsen JP, Tandberg E, Laake K. Predictors
of nursing home placement in Parkinson’s disease: a
population-based, prospective study. Journal of the
American Geriatrics Society. 2000;48(8):938-42.
42. Litvan I, Goldman JG, Troster AI, Schmand BA, Weintraub
D, Petersen RC, et al. Diagnostic criteria for mild cognitive
impairment in Parkinson’s disease: Movement Disorder
Society Task Force guidelines. Movement disorders : official
journal of the Movement Disorder Society. 2012;27(3):349-
56.
43. Janvin CC, Larsen JP, Aarsland D, Hugdahl K. Subtypes of mild
cognitive impairment in Parkinson’s disease: progression
to dementia. Movement disorders : official journal of the
Movement Disorder Society. 2006;21(9):1343-9.
44. Gasca-Salas C, Clavero P, Garcia-Garcia D, Obeso JA,
Rodriguez-Oroz MC. Significance of visual hallucinations
and cerebral hypometabolism in the risk of dementia in
Parkinson’s disease patients with mild cognitive impairment.
Human brain mapping. 2015.
45. Aarsland D, Bronnick K, Williams-Gray C, Weintraub D,
Marder K, Kulisevsky J, et al. Mild cognitive impairment in
Parkinson disease: a multicenter pooled analysis. Neurology.
2010;75(12):1062-9.
46. Williams-Gray CH, Evans JR, Goris A, Foltynie T, Ban M,
Robbins TW, et al. The distinct cognitive syndromes of
[REV. MED. CLIN. CONDES - 2016; 27(3) 363-379]